About us

Astrimmune (Company Registration: 06379008), is a limited, social enterprise company developing treatments for gastrointestinal cancers.  Astrimmune is focussed on the elimination of cancer growth factors that are not yet commercialised  and is progressing a new immunogen vaccine candidate for use in gastro-intestinal cancers.  The distillation of their prior knowledge, coupled with a research programme to refine patient selection to identify the most responsive patients, provides for an accelerated, low cost development path with an increased chance of successful product registration in the EU and the US.